How long do you need to take neratinib/neratinib (He Li'an) continuously?

Neratinib/Neratinib is an irreversible pan-HER inhibitor that mainly inhibits the proliferation and survival of tumor cells by inhibiting the phosphorylation of HER1, HER2 and HER4 receptors and blocking downstream signaling pathways. The drug was originally developed by the American company Puma Biotechnology and later produced by Excella GmbH & Co. KG. According to the guidelines, neratinib is widely used in clinical practice as an extended adjuvant treatment for patients with HER2-positive early breast cancer and can also be used in combination with capecitabine for HER2-positive advanced or metastatic breast cancer.

In the intensive adjuvant treatment of early breast cancer, neratinib is usually recommended to be taken orally daily240 mg (6 tablets) with meals to ensure stable drug absorption. The course of treatment is usually one year or until the disease recurs. Overseas studies have pointed out that continuous medication for 12 months can prolong the disease-free survival (DFS) of patients. Especially for patients who have previously received trastuzumab treatment, neratinib can further reduce the risk of recurrence. Its mechanism is to block the "residual pathway" of HER2 signaling to prevent cancer cells from being activated again, thereby achieving long-term prevention and control.

For patients with advanced or metastatic breast cancer, neratinib needs to be used in combination with capecitabine, according to a 21-day cycle: 240 mg of neratinib is taken daily for days 1 to 21, and combined with capecitabine on days 1 to 14, until disease progression or unacceptable toxicity occurs. Since long-term use may cause reactions such as diarrhea, fatigue, or elevated liver enzymes, patients need to gradually adjust the dosage under the guidance of a doctor. Overseas experience shows that rational use of antidiarrheal drugs and taking them with meals can significantly reduce gastrointestinal adverse reactions.

In general, the medication cycle of neratinib needs to be evaluated in stages according to the condition. Early-stage patients mostly require a fixed course of treatment (about 12 months), while late-stage patients depend on tumor response and tolerance.

Reference materials:https://en.wikipedia.org/wiki/Neratinib